. 2016 Jun;3(2):29–34. doi: 10.1530/ERP-16-0005
This work is licensed under a Table 1.
Characteristics of the study population.
| Characteristics | CAD (+) group | No CAD group (n=10) | Total (n=71) | P-value | |
|---|---|---|---|---|---|
| High-SS group (n=25) | Low-SS group (n=36) | ||||
| Male (n%) | 19 (76) | 22 (67) | 6 (60) | 49 (69) | NS |
| Age (years) | 61±12 | 64±10* | 55±13 | 62±11 | 0.05 |
| Obesity (n%) | 4 (16) | 2 (6) | 1 (10) | 7 (10) | NS |
| Diabetes (n%) | 9 (36) | 15 (42) | 1 (10) | 25 (35) | NS |
| Hypertension (n%) | 15 (60) | 21 (58) | 4 (40) | 40 (56) | NS |
| Dyslipidaemia (n%) | 11 (44) | 18 (50) | 3 (30) | 32 (45) | NS |
| Smoking (n%) | 9 (36) | 16 (42) | 1 (10) | 26 (37) | NS |
| Chronic kidney disease (n%) | 4 (16) | 5 (14) | 2 (20) | 11 (15) | NS |
| Heart rate (bpm) | 68±8* | 65±8 | 62±4 | 66±8 | 0.05 |
| ARB and/or ACE inhibitors (n%) | 13 (52)* | 13 (36) | 1 (10) | 27 (38) | 0.05 |
| Calcium channel blockers (n%) | 7 (28) | 10 (28) | 2 (20) | 19 (27) | NS |
| Diuretics (n%) | 5 (20) | 5 (14) | 1 (10) | 11 (15) | NS |
| β-blockers (n%) | 10 (40) | 16 (44) | 3 (30) | 29 (41) | NS |
NS, non-significant.
*P<0.05 vs control group.